AiCure

Ethics/Regulatory

FDA staff returns to work

Friday, October 18, 2013 09:02 AM

A message on the FDA website from Health and Human Service secretary Katheleen Sebelius thanked readers for their patience throughout the lapse in Federal funding. She said, “The uncertainty of the past few weeks has created many difficult situations, and the shutdown has imposed hardships on many employees as well as the public we serve.”

More... »


Health advocates react to California Gov.’s rejection of patient access to biosimilars bill

Monday, October 14, 2013 02:19 PM

Supporters of SB 598 are reacting with disappointment over California Gov. Jerry Brown’s veto of legislation that would have made the necessary updates to state regulations in anticipation of FDA approval of biosimilar medicines. SB 598 received overwhelming bipartisan approval throughout the legislative process, passing 176-13 in five committees and three floor votes in the Assembly and Senate.

More... »

Subscribe to The CenterWatch Monthly

PPMD calls for new collaborative approach to benefit/risk analysis with FDA

Wednesday, October 9, 2013 02:07 PM

Parent Project Muscular Dystrophy (PPMD), a patient advocacy organization fighting to end Duchenne muscular dystrophy, has proposed a collaboration with the FDA to initiate a rare disease benefit/risk pilot program using Duchenne as the initial therapeutic area.

More... »

FDA postpones Advisory Committee meeting due to government shutdown

Wednesday, October 9, 2013 02:06 PM

ALK, a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment, has announced that due to the U.S. government shutdown, the FDA has temporarily postponed the Allergenic Products Advisory Committee meeting scheduled for Nov. 6 to discuss the Biologic License Application (BLA) for the investigational grass allergy immunotherapy (AIT) tablet. The FDA has not yet confirmed a new date for the Advisory Committee meeting.

More... »

Scottish drug approval process to become more transparent

Wednesday, October 9, 2013 11:50 AM

Scottish patients will benefit from an increased range of new medicines due to changes announced by Alex Neil, the Scottish health secretary.

More... »

Stakeholders endorse Drug Quality and Security Act

Monday, October 7, 2013 01:18 PM

A broad range of stakeholders has endorsed the Drug Quality and Security Act, legislation introduced by Senate and House health policy leaders to address high-risk drug compounding practices and secure the pharmaceutical supply chain. The bill would improve drug safety and help prevent a future public health crisis like the 2012 meningitis outbreak tied to the New England Compounding Center.

More... »

FDA's report on chronic fatigue syndrome reveals impact, progress needed

Friday, October 4, 2013 01:23 PM

Pandora Org, a national nonprofit ME/CFS advocacy organization, and other patient organizations say a recent report from the FDA shows it must take further action to open up opportunities for ME/CFS drug development. Titled The Voice of the Patient, this report is a detailed summary of an April 25 FDA patient-focused drug development meeting, the first of its kind, at which patients explained the reality of Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS).

More... »

Government shutdown already affecting clinical trials industry

Friday, October 4, 2013 08:58 AM

Last week, when the government shutdown began, stories of children with cancer unable to get into potentially life-saving trials at the National Institutes of Health (NIH) were the first clinical research-related ramifications reported.

More... »

URAC launches revised Case Management Accreditation program

Wednesday, September 11, 2013 01:48 PM

URAC has launched its enhanced Case Management Accreditation Standards and Measures, with an optional Transitions of Care Designation. URAC’s Case Management Accreditation program allows for the application of case management standards across all care settings, helping organizations demonstrate outcomes-based, patient-centered, high-value quality care.

More... »

EFPIA responds to EMA draft policy on access to clinical trial data

Wednesday, September 11, 2013 01:20 PM

EFPIA, representing the research-based pharmaceutical industry in Europe with a membership of 33 national associations and 40 pharmaceutical companies, has concerns about the EMA draft policy (0070) on publication and access to clinical trial data, saying it carries negative implications for public health in its failure to adequately protect the interests of patients and the research from which they benefit.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs